Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Approves Abuse-Resistant Painkiller

By Drug Discovery Trends Editor | June 20, 2011

NEW YORK (AP) – Pfizer Inc. and Acura Pharmaceuticals Inc. said the Food and Drug Administration approved a powerful painkiller that is designed to be harder to abuse.

The FDA cleared marketing of Oxecta as an immediate-release treatment for acute or moderate-to-severe pain. The drug also contains niacin, which causes irritation and flushing if patients take extra doses to get high.

Oxecta is similar to Purdue Pharma LP’s OxyContin, the top-selling painkiller in the U.S. Regulators and health officials have pushed hard to get alternatives on the market after reports showed millions of people were abusing OxyContin and other prescription painkillers.

Acura and King Pharmaceuticals developed Oxecta under the name Acurox. Pfizer of New York bought King for $3.6 billion, and Oxecta is the first of King’s drugs to be approved since the deal closed in March. A second approval could come Thursday, as Pfizer is waiting for the FDA to return a decision on the drug candidate Remoxy.

OxyContin is an extended-release painkiller, however, and Citi Investment Research analyst John Boris said those drugs represent a larger market. Boris said annual sales of Oxecta could rise as high as $100 million, but Remoxy sales could reach $500 million a year.

Unlike those drugs, Oxecta is designed to start working right away.

Boris said he does not believe Remoxy will be approved this week, as Pfizer has disclosed a manufacturing issue that could delay approval. Remoxy was developed by Durect Corp. and licensed by Pain Therapeutics Inc. Pfizer now holds a sublicense from Pain Therapeutics.

Date: June 20, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50